TheraVet Reports Further Achievements on Its Osteosarcoma Program

GOSSELIES, Belgium, December 06, 2023--Regulatory News: TheraVet (ISIN: BE0974387194 – ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, updates on the Osteosarcoma Program achievements in 2023.

Related Keywords

France ,United Kingdom ,Belgium ,Gosselies ,Waals Gewest ,Brussels ,Bruxelles Capitale ,Paris ,France General ,United States ,Martin Nicolas Fossiez ,Osteosarcoma Cementoplasty ,Newcap Belgique ,Enrico Bastianelli ,Arthur Rouill ,University Of Florida ,Osteosarcoma Reference Centers ,Financial Communications ,Osteosarcoma Program ,Regulatory News ,Chief Executive Officer ,Bone Diseases ,Clinical Cases ,Innovative Solution ,Osteosarcoma ,International Credibility ,Steosarcoma Program Achievements ,Tereotactic Radiotherapy ,